Clinical Trials Directory

Trials / Completed

CompletedNCT03692104

US-CT Fusion for Post Implant Dosimetry

Comparison Between Postoperative Ultrasound-CT Fusion With MRI-CT Fusion for Postimplant Dosimetry for Prostate LDR Permanent Seed Brachytherapy

Status
Completed
Phase
Study type
Observational
Enrollment
25 (actual)
Sponsor
British Columbia Cancer Agency · Academic / Other
Sex
Male
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.

Detailed description

25 participants undergoing permanent seed prostate brachytherapy will be approached to undergo collection of prostate US images at the completion of their procedure. This will add approximately 5 minutes to the duration of their brachytherapy procedure. The US study will not entail any discomfort or risk to participants as they are still under anesthesia for the implant procedure. The institution standard of care for quality assurance will be complied with, obtaining a CT and MRI of the prostate at 30 days after the procedure. These will be co-registered and analyzed in the normal fashion. In addition, the post implant US images will also be co-registered with the CT and the resulting dosimetric parameters compared.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTtransrectal ultrasoundUse of US for post implant quality assessment

Timeline

Start date
2017-11-03
Primary completion
2018-02-28
Completion
2019-12-31
First posted
2018-10-02
Last updated
2020-01-27

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03692104. Inclusion in this directory is not an endorsement.